Elranatamab

ApprovedMonoclonal antibody

Elranatamab is a monoclonal antibody that works as a T Cell Surface Glycoprotein CD3 Binding Agent; Tumor Necrosis Factor Receptor Superfamily Member 17 Binding Agent.[2] It is being used across 5 indications, with its most advanced program in Approved.[1]

Elranatamab is one of 75 small molecule programs targeting Asymptomatic Myeloma. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Asymptomatic MyelomaActive, not recruiting

AL AmyloidosisActive, not recruiting

Multiple MyelomaRecruiting

Haematological MalignancyRecruiting

Relapsed or Refractory Multiple MyelomaRecruiting

Asymptomatic MyelomaPhase 2

Active, not recruiting

AL AmyloidosisPhase 1

Active, not recruiting

Multiple MyelomaApproved

Recruiting

Haematological MalignancyPreclinical

Recruiting

Relapsed or Refractory Multiple MyelomaPhase 1

Recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Elranatamab

Pfizer

Approved

32 2

Prolia

Amgen

Preclinical

5 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 5

Adriamycin

GGynecologic Oncology Group

Preclinical

9 6

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 7

Intron a

Systemic Therapy

1 9

Abecma

Bristol-Myers Squibb

Preclinical

4 10

Oblimersen Sodium

NNational Cancer Institute (NCI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Multiple Myeloma

NCT04649359

Q1 2027

PreclinicalRecruiting

Haematological Malignancy

NCT04068597

Q2 2027

Phase 3Recruiting

Multiple Myeloma

NCT05020236

Phase 1/2Recruiting

Multiple Myeloma

NCT06988488

Q3 2027

Phase 2Recruiting

Elranatamab

NCT06015542

Phase 1Recruiting

Relapsed or Refractory Multiple Myeloma

NCT05927571

Clinical

Trials by Indication[1]

Multiple Myeloma32 trials

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07382739·34 enrolled

Elranatamab in R/R Multiple Myeloma

Recruiting·MMassachusetts General Hospital·Phase 2·NCT06138275·32 enrolled

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Recruiting·DDavid Avigan·Phase 1·NCT06799026·25 enrolled

Show 29 more trials

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06207799·40 enrolled

Elranatamab in Relapsed/Refractory Multiple Myeloma

Recruiting·UUniversity of California, San Diego·Phase 2·NCT06711705·33 enrolled

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT06215118·87 enrolled

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT05675449·90 enrolled

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

Recruiting·UUniversity of Miami·Phase 2·NCT06997081·104 enrolled

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Completed· Pfizer logo

Pfizer·Phase 2·NCT05228470·39 enrolled

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

Completed· Pfizer logo

Pfizer·Phase 2·NCT05014412·86 enrolled

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT06988488·62 enrolled

A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Completed· Pfizer logo

Pfizer··NCT05565391·508 enrolled

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Completed· Pfizer logo

Pfizer··NCT05932290·514 enrolled

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Recruiting·SStichting European Myeloma Network·Phase 2·NCT06183489·50 enrolled

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT05020236·944 enrolled

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

Completed· Pfizer logo

Pfizer··NCT06504524·633 enrolled

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Recruiting·CC4 Therapeutics, Inc.·Phase 1·NCT07280013·60 enrolled

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 1·NCT06121843·147 enrolled

Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

Recruiting·YYOUNGIL KOH·Phase 1/2·NCT06645678·75 enrolled

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Recruiting·SSCRI Development Innovations, LLC·Phase 2·NCT06974786·100 enrolled

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies

Completed· Pfizer logo

Pfizer··NCT06592222·4 enrolled

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Completed· Pfizer logo

Pfizer·Phase 1·NCT04798586·4 enrolled

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Active, not recruiting· Pfizer logo

Pfizer·Phase 2·NCT04649359·187 enrolled

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

No longer available· Pfizer logo

Pfizer··NCT05462639

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

Recruiting·OOntario Clinical Oncology Group (OCOG)·Phase 2·NCT06421675·40 enrolled

The Norwegian Immunotherapy in Multiple Myeloma Study

Recruiting·SSt. Olavs Hospital··NCT06855121·400 enrolled

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT05317416·811 enrolled

A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Multiple Myeloma

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT06106945·226 enrolled

A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT06152575·492 enrolled

AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT05623020·1,116 enrolled

ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES

Recruiting· Pfizer logo

Pfizer·Approved·NCT06057402·80 enrolled

ELDORADO: a Randomized Phase II Trial of Elranatamab or Daratumumab in Combination With Lenalidomide, Bortezomib, and Dexamethasone (RVd Lite) in Newly Diagnosed, Transplant Ineligible/Deferred Multiple Myeloma

Not yet recruiting·MMassachusetts General Hospital·Phase 2·NCT07247097·160 enrolled

Elranatamab5 trials

Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

Active, not recruiting· Pfizer logo

Pfizer··NCT06581848·150 enrolled

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06947083·39 enrolled

Self-administration of Subcutaneous Elranatamab in the Patients' Homes.

Recruiting·TThomas Lund·Phase 2·NCT06015542·20 enrolled

Show 2 more trials

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

No longer available· Pfizer logo

Pfizer··NCT05238311

ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab

Not yet recruiting·PPeking University People's Hospital··NCT07320326·159 enrolled

Relapsed/Refractory1 trial

ELISA in Relapsed/Refractory MM

Recruiting·MMassachusetts General Hospital·Phase 2·NCT06832865·30 enrolled

Maintenance Therapy1 trial

Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

Not yet recruiting·NNantes University Hospital·Phase 2·NCT06931704·176 enrolled

AL amyloidosis1 trial

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Recruiting·—·Phase 1/2·NCT06569147·49 enrolled

4 more indications

Lenalidomide1 trial

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Recruiting·IIntergroupe Francophone du Myelome·Phase 3·NCT06918002·824 enrolled

Relapsed or Refractory1 trial

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

Recruiting·PPETHEMA Foundation·Phase 2·NCT06282978·50 enrolled

Relapsed or Refractory Multiple Myeloma1 trial

An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting· Roche logo

Roche·Phase 1·NCT05927571·120 enrolled

Haematological Malignancy1 trial

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.

Recruiting·CCellCentric Ltd.·Preclinical·NCT04068597·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 44 trial records for Elranatamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Elranatamab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Elranatamab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: T Cell Surface Glycoprotein CD3 Binding Agent; Tumor Necrosis Factor Receptor Superfamily Member 17 Binding Agent[2]
Modality: Monoclonal antibody[2]
Highest Phase: Approved[1]
Company: Pfizer

Elranatamab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Multiple Myeloma32 trials

Elranatamab5 trials

Relapsed/Refractory1 trial

Maintenance Therapy1 trial

AL amyloidosis1 trial

Lenalidomide1 trial

Relapsed or Refractory1 trial

Relapsed or Refractory Multiple Myeloma1 trial

Haematological Malignancy1 trial

References

Drug Info

Quick Facts

Related News